Publications by authors named "D Bello-Roufai"
Background Neoadjuvant chemoimmunotherapy (NACI) has significantly increased the rate of pathologic complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC), although predictors of response to this regimen have not been identified. Purpose To investigate pretreatment perfusion MRI-based radiomics as a predictive marker for pCR in patients with TNBC undergoing NACI. Materials and Methods This prospective study enrolled women with early-stage TNBC who underwent NACI at two different centers from August 2021 to July 2023.
View Article and Find Full Text PDFPurpose: This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes.
Experimental Design: Multiplexed immune profiling and cell clustering analysis were performed on paired matched ovarian cancer samples to characterize the immune tumor microenvironment (iTME) at diagnosis and under NACT in patients enrolled in the CHIVA trial (NCT01583322).
Results: Several immune cell (IC) subsets and immune coregulators were quantified pre/post-NACT.
Background: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results.
Methods: We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases.
Results: This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023.
Article Synopsis
- The study examines the entire pathway of older adults’ participation in cancer clinical trials, identifying rates of non-invitation and refusal.
- It highlights sociocultural factors, such as social isolation and family dynamics, as major reasons for lower participation rates among older patients.
- The findings indicate that improving inclusion in clinical trials should focus on the interaction between healthcare professionals and patients, rather than solely on the patients themselves.
Objective: HER2 mutations are associated with poor prognosis and are detected in 3-6% of cervical cancers. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, had activity in several HER2-mutant cancer types in the phase 2 SUMMIT basket study. We present updated and final results from the cervical cancer cohort of SUMMIT.
View Article and Find Full Text PDF